Dual effect of the Nrf2 inhibitor for inhibition of HCV and cell proliferation
Ontology highlight
ABSTRACT: We investigated whether brusatol, an Nrf2 inhibitor, has dual effects as anti-HCV and anti-hepatocellular carcinoma (HCC) and whether brusatol can enhance the similar dual effects of sorafenib. We showed that brusatol has dual effects as anti-HCV and anti-HCC and can enhance the similar in vitro effect by sorafenib and that there is potential of combination therapy of brusatol and sorafenib for HCV-related HCC.
ORGANISM(S): Homo sapiens
PROVIDER: GSE98920 | GEO | 2018/06/01
REPOSITORIES: GEO
ACCESS DATA